Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2015

 

 

Alder BioPharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36431   90-0134860
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

11804 North Creek Parkway South

Bothell, WA

   98011
(Address of principal executive offices)   (Zip Code)

(425) 205-2900

Registrant’s telephone number, including area code:

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 1, 2015, Peter Bisgaard notified Alder BioPharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of the Directors of the Company (the “Board”), effective June 8, 2015. In submitting his resignation, Mr. Bisgaard did not express any disagreement on any matter relating to the Company’s operations, policies or practices. At the time of his resignation, Mr. Bisgaard served on the audit committee. Effective as of June 8, 2015, the Board appointed Dr. Deepa Pakianathan to its audit committee. The audit committee, as reconstituted, consists of Dr. Heather Preston (chairman), Dr. Clay Siegall and Dr. Deepa Pakianathan.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Alder BioPharmaceuticals, Inc.
Dated: June 5, 2015
By:

/s/ Randall C. Schatzman

Randall C. Schatzman, Ph.D.
President and Chief Executive Officer